Drugs and patents in ATC class A06A - DRUGS FOR CONSTIPATION

Last updated: February 19, 2026

This report analyzes the patent landscape for drugs treating constipation (ATC Class A06A). Key findings indicate a mature market with established players and a steady flow of incremental innovation focused on improved efficacy, safety profiles, and novel delivery mechanisms. The patent expirations for several blockbuster drugs are imminent or have passed, creating opportunities for generic competition and biosimil development. Emerging trends include the investigation of microbiome-modulating therapies and compounds targeting specific gastrointestinal signaling pathways.

What are the Dominant Therapeutic Classes within A06A?

The A06A classification encompasses a range of pharmacological agents designed to treat constipation. These can be broadly categorized by their mechanism of action, with the following being the most prevalent:

Laxatives: This is the largest sub-category, further divided into:
- Bulk-forming laxatives: Agents that absorb water and swell in the intestine, promoting bowel movements. Examples include psyllium and methylcellulose.
- Stimulant laxatives: Drugs that directly stimulate intestinal motility. Senna and bisacodyl are common examples.
- Osmotic laxatives: These draw water into the colon to soften stool. Polyethylene glycol (PEG) and lactulose are prominent within this group.
- Stool softeners: Surfactants that incorporate water and fat into the stool, making it easier to pass. Docusate sodium is a primary example.
Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs): Developed primarily to counteract opioid-induced constipation (OIC), these drugs block the constipating effects of opioids in the gut without affecting their central analgesic properties. Naloxegol, methylnaltrexone, and naldemedine are key drugs in this class.
Secretagogues: These drugs increase fluid secretion into the intestinal lumen, promoting motility and stool passage. Lubiprostone (a chloride channel activator) and linaclotide and plecanatide (guanylate cyclase-C agonists) are significant examples.

What are the Key Patent Expiration Trends for A06A Drugs?

Patent expirations are a critical factor influencing market dynamics, opening avenues for generic entry and price erosion. For A06A drugs, several significant expirations have occurred or are projected in the near future:

Blockbuster Laxatives: Many older, widely used laxatives, such as senna and bisacodyl, have long-expired patents, allowing for extensive generic availability and low price points. Lactulose patents have also expired globally.
Polyethylene Glycol (PEG) Formulations: While the foundational patents for PEG have expired, innovator companies have sought and obtained patents on specific formulations, dosages, and combinations, extending market exclusivity for certain branded products. However, the broad utility of PEG ensures a competitive generic market for basic formulations.
Opioid-Induced Constipation (OIC) Drugs:
- Naloxegol (Movantik): Key patents have begun to expire in various major markets, with further expirations anticipated in the coming years. This has led to the emergence of generic versions [1].
- Methylnaltrexone (Relistor): Similar to naloxegol, patent cliffs are impacting methylnaltrexone, with generic alternatives becoming available in several regions.
- Naldemedine (Symproic): Patent protections for naldemedine are also subject to upcoming expirations, paving the way for generic competition.
Secretagogues:
- Lubiprostone (Amitiza): While initial composition of matter patents have expired, formulation and method of use patents have provided continued protection for branded products. However, generic entry is becoming more prevalent for established indications.
- Linaclotide (Linzess) and Plecanatide (Trulance): These newer agents benefit from more recent patent filings, providing them with longer periods of market exclusivity. However, ongoing patent litigation and the potential for invalidation are factors to monitor.

The table below summarizes patent expiration trends for select A06A drugs:

Drug Name	Active Ingredient(s)	Primary Indication(s)	Original Approval Year	Key Composition of Matter Patent Expiration (Approximate, Varies by Region)	Current Market Status
Movantik	Naloxegol	Opioid-Induced Constipation (OIC)	2014	2025-2028	Generic entry has commenced in some markets.
Relistor	Methylnaltrexone	OIC	2008	2020-2025	Generic versions are available.
Symproic	Naldemedine	OIC	2017	2030-2033	Exclusivity period is ongoing, with future expiration anticipated.
Amitiza	Lubiprostone	Chronic Idiopathic Constipation, OIC	2006	Patents have expired, but formulation and method of use patents extend some protection.	Generic versions are available for certain indications.
Linzess	Linaclotide	Chronic Idiopathic Constipation, IBS-C	2012	2027-2030 (composition of matter)	Market exclusivity for branded product is ongoing.
Trulance	Plecanatide	Chronic Idiopathic Constipation, IBS-C	2017	2030-2033 (composition of matter)	Market exclusivity for branded product is ongoing.

Note: Patent expiration dates are approximate and vary significantly by jurisdiction. This table represents general trends and does not constitute a comprehensive legal opinion.

What is the Competitive Landscape of A06A Drug Patents?

The patent landscape for A06A drugs is characterized by a mix of early-stage, broad composition of matter patents and later-stage, narrower patents focusing on formulations, manufacturing processes, and new indications.

Dominant Innovators: Companies that developed the more recent and specialized agents, such as Ironwood Pharmaceuticals (linaclotide), Synergy Pharmaceuticals (dolcanatide - though its future is uncertain), and Astellas Pharma (naldemedine), hold significant patent portfolios for their respective drugs.
Generic Manufacturers: A large number of generic drug manufacturers are active in the A06A space. Their patent strategy typically involves challenging existing patents or developing non-infringing formulations once primary patents expire. Companies like Teva Pharmaceuticals, Mylan (Viatris), and Sun Pharma are significant players.
Patent Thickets: For some established drugs, a "patent thicket" exists. This involves numerous patents covering various aspects of the drug, making it challenging for generic competitors to navigate and potentially delaying market entry. This strategy is more common for drugs with significant commercial value.
Biosimil Considerations: While the A06A class primarily consists of small molecules, the increasing trend of biologic development in other therapeutic areas suggests that future innovations in constipation treatment could involve biologics, bringing biosimilar competition into play. However, for the current A06A landscape, biosimilarity is not a primary concern.
Geographic Variations: Patent protection and enforcement vary considerably across different countries. A patent may expire in one region while remaining valid in another, influencing the global rollout of generics.

What are Emerging Trends in A06A Patent Filings?

Recent patent filings in the A06A domain reveal a focus on addressing unmet needs and refining existing therapies. Key emerging trends include:

Microbiome Modulators: There is a growing interest in therapies that target the gut microbiome to alleviate constipation. Patents are being filed for probiotics, prebiotics, and synbiotics designed to restore a healthy gut flora and improve transit time. This area represents a significant shift towards understanding the complex interplay of gut bacteria and bowel function.
Novel Signaling Pathway Targets: Research is exploring new molecular targets involved in intestinal regulation. This includes patents for compounds that modulate other receptor systems beyond guanylate cyclase or chloride channels, aiming for greater specificity and reduced side effects.
Combination Therapies: Patents are emerging for fixed-dose combinations of existing agents or novel combinations designed to provide synergistic effects. This strategy aims to improve efficacy for patients with complex or refractory constipation.
Improved Delivery Systems: Innovation in drug delivery is also evident. Patents are being sought for extended-release formulations, orally disintegrating tablets, and other novel dosage forms that enhance patient compliance and therapeutic outcomes.
Personalized Medicine Approaches: While still nascent, there are early indications of patent filings related to diagnostic methods or companion diagnostics that could guide treatment selection based on a patient's specific genetic or physiological profile.

What are the Patent Challenges and Opportunities within A06A?

The A06A patent landscape presents both challenges and opportunities for pharmaceutical companies and investors.

Challenges:

Patent Expirations and Generic Erosion: The impending or ongoing expiration of patents for established OIC drugs and older laxatives leads to significant price reductions and market share loss for innovator products.
Patent Litigation: The high commercial value of some A06A drugs leads to extensive patent litigation, with generic companies frequently challenging innovator patents. This can result in costly legal battles and uncertainty regarding market exclusivity.
Regulatory Hurdles: Bringing novel constipation treatments to market requires navigating complex regulatory pathways, which can be time-consuming and expensive, regardless of patent protection.
Evolving Standard of Care: The treatment of constipation is dynamic, with new guidelines and therapeutic options constantly emerging, potentially rendering existing patented therapies obsolete or less competitive.

Opportunities:

Generic Entry: For generic manufacturers, the expiration of key patents presents a clear opportunity to enter the market with lower-cost alternatives, capturing a significant share of the patient population.
Orphan Indications and Niche Markets: Patents for drugs targeting specific subtypes of constipation or rare gastrointestinal disorders may offer longer periods of exclusivity and less intense competition.
Reformulation and New Indications: Innovator companies can extend market exclusivity by developing and patenting new formulations, delivery methods, or new uses for existing drugs, provided these offer a tangible benefit.
Novel Mechanism of Action: Companies developing drugs with entirely new mechanisms of action for constipation, particularly those targeting the microbiome or novel signaling pathways, stand to gain significant market share and robust patent protection, provided their innovations are scientifically sound and meet unmet clinical needs.
Acquisition Targets: Emerging companies with promising preclinical or early-clinical stage A06A candidates backed by strong patent protection can become attractive acquisition targets for larger pharmaceutical firms looking to bolster their pipeline.

Conclusion

The A06A drug market is characterized by a mature segment with widespread generic availability and an emerging segment focused on novel mechanisms, improved formulations, and specialized indications. The strategic management of patent portfolios, coupled with a keen understanding of upcoming expirations and the competitive landscape, is crucial for both innovator and generic companies. Emerging research into the gut microbiome and novel signaling pathways offers fertile ground for future patent filings and therapeutic innovation.

Key Takeaways

A significant number of patents for established A06A drugs, particularly older laxatives and OIC treatments like naloxegol and methylnaltrexone, are expiring or have expired, facilitating generic competition.
Innovator companies are increasingly focusing on patenting novel formulations, delivery systems, and combination therapies to extend exclusivity for established drugs.
Emerging research and patent filings indicate a strong trend towards therapies targeting the gut microbiome and novel gastrointestinal signaling pathways.
The A06A patent landscape presents opportunities for generic manufacturers through patent expirations and for innovators through the development of novel mechanisms of action and improved therapeutic profiles, with patent litigation remaining a significant factor.

Frequently Asked Questions

Which A06A drugs are currently facing the most significant patent cliffs in the next five years? Naloxegol (Movantik) and naldemedine (Symproic) are anticipated to experience significant patent expirations in major markets between 2025 and 2028, leading to increased generic competition.
Are there any patent-protected biologics currently in development for constipation? While the current A06A market is dominated by small molecules, the broader trend in pharmaceuticals suggests potential for biologic development targeting the gut microbiome or specific inflammatory pathways related to constipation in the future. However, no dominant biologic therapies are currently in late-stage development or approved within the A06A classification itself.
What is the typical duration of patent protection for a newly approved A06A drug? A new chemical entity for A06A typically receives 20 years of patent protection from the filing date, with potential extensions available through mechanisms like patent term restoration in the U.S. and supplementary protection certificates in Europe, to compensate for regulatory review delays.
How do patent strategies for OIC drugs differ from those for chronic idiopathic constipation drugs? Patents for OIC drugs often focus on their specific mechanism of antagonism of opioid receptors in the periphery, while patents for chronic idiopathic constipation drugs may emphasize novel receptor targets (e.g., guanylate cyclase-C) or mechanisms that promote fluid secretion and motility. Both classes also see patents on formulations and delivery methods.
What are the main areas of innovation being protected by recent A06A patent filings? Recent patent filings are concentrating on microbiome-modulating therapies (probiotics, prebiotics), compounds targeting novel gastrointestinal signaling pathways, improved drug delivery systems (e.g., extended-release), and fixed-dose combination therapies.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvalsand-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Drugs in ATC Class A06A

Subclasses in ATC: A06A - DRUGS FOR CONSTIPATION

Patent Landscape Analysis: ATC Class A06A - Drugs for Constipation